<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="44669">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02524782</url>
  </required_header>
  <id_info>
    <org_study_id>D6240C00001</org_study_id>
    <nct_id>NCT02524782</nct_id>
  </id_info>
  <brief_title>A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1, combined Single Ascending Dose (SAD) and Multiple-ascending Dose (MAD) study to
      evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
      MEDI4166 in Subjects with Type 2 Diabetes Mellitus (T2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a first time in human (FTIH), Phase 1, randomized, double-blind study to
      evaluate the safety, tolerability, PK, and PD of MEDI4166 administered as both single and
      multiple ascending doses to subjects with T2D.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Treatment emergent adverse events (TEAEs) and serious adverse events (TESAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>12 lead electrocardiogram including RR, PR, QRS, QT and QTc intervals</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory rate)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Clinical laboratory assessments (serum chemistry, hematology, urinalysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change in glucose AUC measured up to 240 minutes after mixed meal tolerance test (MMTT) from baseline to Day 36</measure>
    <time_frame>36 days post dosing</time_frame>
    <description>Part B: Change in glucose AUC measured up to 240 minutes after mixed meal tolerance test (MMTT) from baseline to Day 36</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Change in LDL-C from baseline to Day 36</measure>
    <time_frame>36 days post dosing</time_frame>
    <description>Part B: Change in LDL-C from baseline to Day 36</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetics of MEDI4166, maximum plasma concentration (Cmax)</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Part A: Pharmacokinetics of MEDI4166, maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetics of MEDI4166, area under the curve concentration (AUC)</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Part A: Pharmacokinetics of MEDI4166, area under the curve concentration (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in LDL-C</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Part A: Change from baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Proportion of subjects with Anti-drug Antibodies (ADA) to MEDI4166</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Part A: Proportion of subjects with ADA to MEDI4166</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Treatment emergent adverse events (TEAEs) and serious adverse events (TESAEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>12 lead electrocardiogram including RR, PR, QRS, QT and QTc intervals</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Vital signs (systolic and diastolic blood pressure, pulse rate, temperature, and respiratory rate)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Clinical laboratory assessments (serum chemistry, hematology, urinalysis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of subjects with adverse events as a measure of safety and tolerability of MEDI4166</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Physical examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetics of MEDI4166, maximum plasma concentration (Cmax)</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Part B: Pharmacokinetics of MEDI4166, maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetics of MEDI4166, area under the curve concentration (AUC)</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Part B: Pharmacokinetics of MEDI4166, area under the curve concentration (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from baseline in fructosamine levels</measure>
    <time_frame>36 days post dosing</time_frame>
    <description>Part B: Change from baseline in fructosamine levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Proportion of subjects with ADA to MEDI4166</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Part B: Proportion of subjects with ADA to MEDI4166</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Part A: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Change from baseline in glucose AUC up to 240 minutes</measure>
    <time_frame>43 days post dosing</time_frame>
    <description>Part A: Change from baseline in glucose AUC up to 240 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)</measure>
    <time_frame>71 days post dosing</time_frame>
    <description>Part B: Pharmacokinetics of MEDI4166, time to maximum observed plasma drug concentration (Tmax)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">497</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>MEDI-4166</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-4166 administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI-4166</intervention_name>
    <description>MEDI-4166 administered subcutaneously</description>
    <arm_group_label>MEDI-4166</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes, ages 18-65

          -  Must provide written informed consent

          -  BMI&gt;=25 and =&lt;42

          -  Venous access suitable for multiple cannulations

          -  Vital signs within normal specified ranges

          -  Females must be non-lactating and non-childbearing potential

          -  Males must practice 2 effective contraceptive measures if sexually active

        Exclusion Criteria:

          -  Any concurrent condition that in the opinion of the investigator would interfere with
             the evaluation of the investigational product

          -  History or presence of gastrointestinal, renal, or hepatic disease or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          -  History of cancer, with the exception of basal cell carcinoma or carcinoma of the
             cervix

          -  Any clinically important illness, medical/surgical procedure, or trauma within 4
             weeks prior to dosing

          -  Positive Hepatitis B, Hepatitis C or HIV test or use of antiretroviral medications at
             screening

          -  Current or previous use of systemic corticosteroids within the past 28 days prior to
             screening

          -  Use of any medicinal products or herbal preparations licensed for weight loss is
             prohibited.

          -  Positive drug screen

          -  Type 1 diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 13, 2017</lastchanged_date>
  <firstreceived_date>August 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MEDI-4166, diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
